Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 4/20 | 0.82 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13587780 | 0.84 | NR3C2 (0.57) | NR3C2KDM4E | |
| SCHEMBL11376558 | 0.75 | NR3C2 (0.52) | NR3C2KDM4EMEN1MAPTALOX15 | |
| SCHEMBL8260688 | 0.74 | KDM4E (0.49) | NR3C2KDM4E | |
| SCHEMBL9765807 | 0.74 | CYP1A2 (0.60) | NR3C2KDM4EALDH1A1MEN1TP53 | |
| SCHEMBL13587764 | 0.73 | NR3C2 (0.70) | NR3C2CACNA1C | |
| SCHEMBL13587768 | 0.72 | NR3C2 (0.56) | NR3C2KDM4E | |
| SCHEMBL9644465 | 0.72 | NR3C2 (0.77) | NR3C2KDM4EMEN1MAPTALOX15 | |
| SCHEMBL13587741 | 0.72 | NR3C2 (0.58) | NR3C2KDM4E | |
| SCHEMBL8867292 | 0.72 | NR3C2 (0.84) | NR3C2KDM4EMEN1MAPTALOX15 | |
| SCHEMBL8257346 | 0.72 | NR3C2 (0.58) | NR3C2CACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298872-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROIDAL RECEPTORS AND CALCIUM CHANNEL ACTIVITIES | IRM LLC (BM) | 2009-12-03 | — | — | US | disclosed |
| WO-2006066011-A2 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROIDAL RECEPTORS AND CALCIUM CHANNEL ACTIVITIES | IRM LLC (BM) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298872-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROIDAL RECEPTORS AND CALCIUM CHANNEL ACTIVITIES | TRPV1, TRPV2, TRPV6 | NR3C2 12/4885KDM4E 3960/4885ALDH1A1 3716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.